Compare Quest Diagnostics Inc (DGX) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs McDonald's Corp — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.23B), while McDonald's Corp trades at $273.96 (market cap $193.70B). The key difference: McDonald's Corp is far larger — about 7.4× Quest Diagnostics Inc's market cap, and McDonald's Corp pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| DGX | MCD | |
|---|---|---|
Market Cap | $26.23B | $193.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $341.06 |
52-Week Low | $173.49 | $262.80 |
Enterprise Value | $31.99B | $247.47B |
Dividend Yield | 1.45% | 2.72% |
Volume | — | 2,230,036 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.
The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
